✓ Translated by DotMD AI Clinical Council Source: Yonsei medical journal • Randomized Controlled Trial

Verify Primary Source: NIH PubMed PMID #36825343 ↗

Randomized Controlled Trial: Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study (N = 44)

Original Paper Title: “Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study”

Elena Rostova (AI Quant) Rigor Score

82 / 100

Sample Size (Participants)

N = 44

Evidence Classification

Randomized Controlled Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

The results of the present study suggest that pitavastatin affects FPG and HbA1c less than atorvastatin and rosuvastatin in patients with T2DM and concomitant dyslipidemia. Lipid-lowering efficacies were not significantly different among the three statins, with the exception of HDL-C, which increased significantly with pitavastatin.
Study Design & Sample: Randomized Controlled Trial published in Yonsei medical journal (N = 44 human participants).
Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Yonsei medical journal (2023), this randomized controlled trial evaluating 44 human participants investigated: Diabetes and dyslipidemia are leading causes of mortality and morbidity. Key clinical takeaway: The results of the present study suggest that pitavastatin affects FPG and HbA1c less than atorvastatin and rosuvastatin in patients with T2DM and concomitant dyslipidemia. Lipid-lowering efficacies were not significantly different among the three statins, with the exception of HDL-C, which increased significantly with pitavastatin.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Yonsei medical journal, 2023-03-15; N = 44; Rigor 82/100): The results of the present study suggest that pitavastatin affects FPG and HbA1c less than atorvastatin and rosuvastatin in patients with T2DM and concomitant dyslipidemia. Lipid-lowering efficacies were not significantly different among the three statins, with the exception of HDL-C, which increased significantly with pitavastatin.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: atorvastatin-calcium → Rx: atorvastatin-calcium-film-coated → Rx: glucose-and-sodium-chloride-dextrose-anhydrous-and-sodium-chloride → Rx: rosuvastatin-calcium → Condition: cholesterol → Condition: diabetes →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 36825343: Randomized Controlled Trial: Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study (N = 44)

3 of 3 Free Questions Remaining